Document is current

Article History

Received: 30 August 2022

Accepted: 30 April 2023

First Online: 15 May 2023

Declarations

:

: The protocol, informed consent documents and statistical analysis plan were approved by the Western Institutional Review Board (WIRB) acting as the central single IRB. Patients enrolled in the trial provided written informed consent for participation and all research involving human participants, human material, or human data, was performed in accordance with the Declaration of Helsinki and was approved by an appropriate ethics committee.

: Not applicable.

: JRB reported receiving grants payable his institution from the National Institutes of Health (NIH) for clinical trial work and receiving consulting fees from JAJ LLC. JMC reported receiving personal fees from Bristol Myers Squibb, Pfizer, Abbott, Alnylam, Takeda, Roche, and Sanofi and that his institution has received research funding from CSL Behring. MB reported receiving personal fees for data and safety monitoring board membership from Cerus Corporation. JAK reported receiving consulting fees from GlaxoSmithKline and research funding from Sergey Brin Family Foundation, National Institutes of Health, American Lung Association, and the Patient Centered Outcomes Research Institute. BK reported receiving grants from SOCAR Research SA. PH reported receiving grants from Brigham and Women’s Hospital, NIH, Novartis, and CalciMedica. PMR reported receiving grants from Bristol Myers Squibb and Pfizer and serving as a consultant for work unrelated to this study for Corvidia, Novartis, Flame, Agepha, Inflazome, AstraZeneca, Janssen, Civi Biopharm, SOCAR, Novo Nordisk, Uptton, Omeicos, and Boehringer Ingelheim. No other authors reported disclosures.